• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Antares Pharma, Inc. (AIS) - Financial and Strategic SWOT Analysis Review Product Image

Antares Pharma, Inc. (AIS) - Financial and Strategic SWOT Analysis Review

  • Published: September 2011
  • Region: Global
  • 49 pages
  • GlobalData

FEATURED COMPANIES

  • Elcam Medical
  • Endo Pharmaceuticals Inc.
  • Novavax, Inc.
  • The Medical House PLC
  • Ypsomed AG
  • MORE

Antares Pharma, Inc. (AIS) - Financial and Strategic SWOT Analysis Review

Summary

Antares Pharma, Inc. (Antares Pharma) is a specialty pharmaceutical company engaged in the development and commercialization of novel parenteral therapeutic products using advanced drug delivery systems. The company is focused on topical gel-based products and self-injection pharmaceutical products and technologies. The company has developed three proprietary platforms. Its subcutaneous injection technology platforms include Vision, reusable needle-free injectors; Vibex, disposable pressure-assisted auto injectors and disposable multi-use pen injectors. Antares Pharma applies its drug delivery systems in collaborations with pharmaceutical partners to enhance its partners' drug compounds. It has various multiple development partnerships with leading pharmaceutical companies. The company has a parenteral products division in Minnesota and Minneapolis. Antares Pharma is headquartered at Ewing in New Jersey, the US.

Antares Pharma, Inc. Key Recent Developments

Aug 08, 2011: Antares Pharma Reports Second Quarter 2011Financial and Operating Results
May 09, 2011: Antares Pharma READ MORE >



List of Tables
List of Figures
Section 1 - About the Company
Antares Pharma, Inc. - Key Facts
Antares Pharma, Inc. - Key Employees
Antares Pharma, Inc. - Key Employee Biographies
Antares Pharma, Inc. - Major Products and Services
Antares Pharma, Inc. - Pharmaceutical Pipeline Products Data
Antares Pharma, Inc., Pipeline Products by Therapy Area
Antares Pharma, Inc., Pipeline Products by Development Phase
Antares Pharma, Inc. - Medical Equipment Pipeline Products Data
Antares Pharma, Inc. Pipeline Products by Equipment Type
Antares Pharma, Inc. Pipeline Products by Development Stage
Antares Pharma, Inc. - History
Antares Pharma, Inc. - Company Statement
Antares Pharma, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Antares Pharma, Inc. - Business Description
Antares Pharma, Inc. - SWOT Analysis
SWOT Analysis - Overview
Antares Pharma, Inc. - Strengths
Strength - Distinctive Technology Platforms
Strength - Strong Research and Development Activities
Strength - Strategic Collaborations
Weakness - Lack of Manufacturing Capabilities
Weakness - History of Operating Losses
Weakness - Limited Customer Base
Opportunity - Urinary Incontinence Market
Opportunity - Changing Demographics
Opportunity - Pain Management Market
Threat - Tightening of the FDA’s Regulatory Oversight
Threat - Product Liability Claims
Threat - Competition and Technological Change
Antares Pharma, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Antares Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Antares Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Antares Pharma, Inc., Medical Equipment, Deals By Year, 2005 to YTD 2011
Antares Pharma, Inc., Medical Equipment, Deals By Type, 2005 to YTD 2011
Antares Pharma, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
May 09, 2011: Antares Pharma Reports Product Sales Of $1.4m In Q1 2011
Mar 14, 2011: Antares Pharma Reports Net Loss Of $1.3m For Q4 2010
Nov 10, 2010: Antares Pharma Reports Total Revenues Of $3.12 Million For Q3 2010
Nov 03, 2010: Antares Pharma Receives Qualifying Therapeutic Discovery Project Grants For Anturol And VIBEX MTX Development Programs
Sep 17, 2010: Antares Pharma Announces Senior Management Changes
Aug 12, 2010: Antares Pharma Reports Net Loss Of $1.5 Million For Q2 2010
May 13, 2010: Antares Reports Net Loss Of $1.6 Million For Q1 2010
May 13, 2010: Antares Reports Net Loss Of $1.6 Million For Q1 2010
Mar 23, 2010: Antares Reports Net Loss Of $2.4 Million For Q4 2009
Mar 23, 2010: Antares Pharma Reports Net Loss Of $2.4 Million In Q4 2009
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

The Medical House PLC
Bioject Medical Technologies Inc.
Elcam Medical
Ypsomed AG
Novavax, Inc.
Endo Pharmaceuticals Inc.
Watson Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS